While blocking antibodies against VEGFR-3 are currently tested as anti-angiogenic and anti-metastatic drugs [15], the potential for antagonists of adenosine receptors to inhibit lymphangiogenesis and its deleterious consequences on tumor development and anti-cancer therapies has not been addressed. The gene discussed is FLT4; the disease is neoplasm.